Study of BMS-663513 in Patients With Advanced Cancer

Clinical Trial ID NCT00309023

PubWeight™ 12.59‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00309023

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009 1.81
2 Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013 1.33
3 A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 2009 1.09
4 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
5 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
6 Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol 2013 0.89
7 Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015 0.87
8 SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines 2014 0.85
9 Principles of antibody-mediated TNF receptor activation. Cell Death Differ 2015 0.84
10 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother 2016 0.81
11 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
12 ProtEx technology for the generation of novel therapeutic cancer vaccines. Exp Mol Pathol 2009 0.79
13 Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology 2016 0.75
Next 100